{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:12:23Z","timestamp":1770484343850,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.mcna.2012.04.003","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T04:19:02Z","timestamp":1335845942000},"page":"475-496","source":"Crossref","is-referenced-by-count":26,"title":["Immunotherapies in Rheumatologic Disorders"],"prefix":"10.1016","volume":"96","author":[{"given":"Anne V.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriya K.M.","family":"Ranatunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2012.04.003_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.1780371002","article-title":"Autoimmune disease. A problem of defective apoptosis","volume":"37","author":"Mountz","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.1124978","article-title":"Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication","volume":"312","author":"Pisitkun","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.mcna.2012.04.003_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-7125(05)70504-6","article-title":"Pathogenesis of rheumatoid arthritis","volume":"81","author":"Weyand","year":"1997","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.mcna.2012.04.003_bib4","first-page":"181","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2012.04.003_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/32.suppl_2.3","article-title":"Some molecular mechanisms of glucocorticoid action","volume":"32","author":"Krane","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.yfrne.2007.10.004","article-title":"The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings","volume":"29","author":"Haller","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.mcna.2012.04.003_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.imbio.2009.10.003","article-title":"Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells","volume":"215","author":"Boldizsar","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.mcna.2012.04.003_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bjp.0704474","article-title":"Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells","volume":"135","author":"Croxtall","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mcna.2012.04.003_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2004-12-4790","article-title":"Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn","volume":"106","author":"Lowenberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.mcna.2012.04.003_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.mcna.2012.04.003_bib11","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4049\/jimmunol.156.9.3435","article-title":"Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors","volume":"156","author":"Sajjadi","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.mcna.2012.04.003_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/gut.22.8.642","article-title":"Inhibition of leucocyte motility by drugs used in ulcerative colitis","volume":"22","author":"Rhodes","year":"1981","journal-title":"Gut"},{"key":"10.1016\/j.mcna.2012.04.003_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0016-5085(89)91569-2","article-title":"Inhibition of antibody secretion by 5-aminosalicylic acid","volume":"96","author":"MacDermott","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2012.04.003_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.10766","article-title":"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis","volume":"48","author":"Nesher","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib16","first-page":"1275","article-title":"Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis","volume":"33","author":"Benito-Garcia","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib17","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib18","first-page":"248","article-title":"Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis","volume":"33","author":"Maradit-Kremers","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.280.6212.442","article-title":"Sulphasalazine in rheumatoid arthritis","volume":"280","author":"McConkey","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.mcna.2012.04.003_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/bmj.287.6399.1102","article-title":"Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate","volume":"287","author":"Pullar","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.mcna.2012.04.003_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI1554","article-title":"Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides","volume":"101","author":"Morabito","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2012.04.003_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2012.04.003_bib23","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/0006-2952(87)90262-0","article-title":"Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine","volume":"36","author":"Neal","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mcna.2012.04.003_bib24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","article-title":"Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial","volume":"36","author":"Haagsma","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib25","first-page":"1880","volume":"78","year":"1978","journal-title":"Zh Nevropatol Psikhiatr Im S S Korsakova"},{"key":"10.1016\/j.mcna.2012.04.003_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2012.04.003_bib27","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1177\/096120339600500102","article-title":"The history of antimalarials","volume":"5","author":"Wallace","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.mcna.2012.04.003_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.mcna.2012.04.003_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","article-title":"Mechanism of action of hydroxychloroquine as an antirheumatic drug","volume":"23","author":"Fox","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib30","first-page":"1337","article-title":"Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies","volume":"291","author":"Manzel","year":"1999","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.mcna.2012.04.003_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib32","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.mcna.2012.04.003_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","article-title":"Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival","volume":"17","author":"Siso","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.mcna.2012.04.003_bib35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/0961203308099233","article-title":"Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus","volume":"18","author":"Becker-Merok","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.mcna.2012.04.003_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.mcna.2012.04.003_bib38","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.mcna.2012.04.003_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcna.2012.04.003_bib41","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"53","author":"Fox","year":"1998","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.mcna.2012.04.003_bib42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A\u00a0comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mcna.2012.04.003_bib43","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib44","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/art.1780401018","article-title":"Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group","volume":"40","author":"Stein","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.62.4.291","article-title":"Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial","volume":"62","author":"Gerards","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib46","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/rheumatology\/keg394","article-title":"Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mcna.2012.04.003_bib47","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/art.21796","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib48","first-page":"15","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents","volume":"23","author":"Eugui","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.mcna.2012.04.003_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2249.2003.02269.x","article-title":"Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells","volume":"134","author":"Colic","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.mcna.2012.04.003_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181e93d00","article-title":"Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis","volume":"89","author":"Kamanamool","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.mcna.2012.04.003_bib51","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mcna.2012.04.003_bib52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.7326\/0003-4819-114-12-999","article-title":"Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study","volume":"114","author":"Jeurissen","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2012.04.003_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib54","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.mcna.2012.04.003_bib55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.1993.161","article-title":"Colchicine disposition in human leukocytes after single and multiple oral administration","volume":"54","author":"Chappey","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 8","key":"10.1016\/j.mcna.2012.04.003_bib56","first-page":"S113","article-title":"Antibiotics as disease modifiers in arthritis","volume":"11","author":"Kloppenburg","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.mcna.2012.04.003_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-122-2-199501150-00001","article-title":"Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group","volume":"122","author":"Tilley","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2012.04.003_bib58","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A","article-title":"Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine","volume":"44","author":"O'Dell","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib59","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1016\/S0272-6386(03)00671-1","article-title":"ANCA-positive crescentic glomerulonephritis associated with minocycline therapy","volume":"42","author":"Sethi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0049-0172(99)80004-3","article-title":"Minocycline-induced autoimmune syndromes: an overview","volume":"28","author":"Elkayam","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.amjmed.2004.03.013","article-title":"Refractory neurosarcoidosis: a dramatic response to infliximab","volume":"117","author":"Carter","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2012.04.003_bib62","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/01.WNL.0000034766.13282.33","article-title":"Refractory neurosarcoidosis responding to infliximab","volume":"59","author":"Pettersen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.04.003_bib63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"153","author":"Burns","year":"2008","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.mcna.2012.04.003_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib67","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.04.003_bib68","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib69","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib70","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib71","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib72","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/art.24035","article-title":"Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders","volume":"58","author":"Thurlings","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2012.04.003_bib74","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mcna.2012.04.003_bib75","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A\u00a0pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.mcna.2012.04.003_bib76","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.33412","article-title":"Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a Phase 2 clinical trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib77","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mcna.2012.04.003_bib78","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib79","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.mcna.2012.04.003_bib80","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cyto.2010.03.017","article-title":"IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression","volume":"51","author":"Suzuki","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.mcna.2012.04.003_bib81","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00296-009-1075-4","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production","volume":"30","author":"Hashizume","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.mcna.2012.04.003_bib82","unstructured":"Genentech I. Highlights of prescribing information: Actemra\u00ae (tocilizumab). http:\/\/www.gene.com\/gene\/products\/information\/actemra\/pdf\/pi.pdf. Accessed February 26, 2012."},{"key":"10.1016\/j.mcna.2012.04.003_bib83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.04.003_bib84","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2012.04.003_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis Published Online First:"},{"key":"10.1016\/j.mcna.2012.04.003_bib86","unstructured":"U.S. Food and Drug Administration. FDA approves Benlysta to treat lupus. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm246489.htm. Accessed February 27, 2012."},{"key":"10.1016\/j.mcna.2012.04.003_bib87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14712598.2011.566856","article-title":"Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis","volume":"11","author":"Semerano","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.mcna.2012.04.003_bib88","first-page":"w13108","article-title":"Anti-cytokine vaccination in autoimmune diseases","volume":"140","author":"Delavallee","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.mcna.2012.04.003_bib89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/hum.2010.110","article-title":"Potent antirheumatic activity of a new DNA vaccine targeted to B7-2\/CD28 costimulatory signaling pathway in autoimmune arthritis","volume":"22","author":"Xue","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.mcna.2012.04.003_bib90","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.intimp.2009.12.016","article-title":"CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine\/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model","volume":"10","author":"Zimmerman","year":"2010","journal-title":"Int Immunopharmacol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T11:08:33Z","timestamp":1687432113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712512000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0025712512000685"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2012.04.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}